台灣臨床試驗主持人資料庫|TPIDB

問卷

問卷調查提醒

您好：邀請您填寫網站的問卷意見調查表，讓我們有更多優化及改進的方向，一起提升使用者體驗。

系統通知

此案目前為暫存狀態

編修至YYYY/MM/DD

不開放編輯功能

確認送出

我同意

請先勾選「我同意」

當您勾選「我同意」時，表示您已閱讀、了解並同意接受本「會員同意書及隱私權政策」內容

繁中 EN

TPIDB

TPIDB Outstanding PI Advanced Search 聯絡我們

繁中 EN

TPIDB Outstanding PI

TPIDB > Study Site

Study Site

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Link to Hospital │ Link to Clinical Trial Center

726

Total Beds
258

Total Doctors

IMS@w.tmu.edu.tw
International Medical Center
886-2 29307930*7766/7767/7768
116Taipei CityWun ShanWanFang Hospital 1st Floor (No.111, Sec. 3, Xinglong Rd., Wenshan Dist., Taipei City 116, Taiwan)

Recruiting Trial

74Cases

Site Introduction Principal Investigator List Clinical Trials List

請選擇要匯出的欄位

全選

Plan Title (TW)

Plan Title (EN)

Plan No

NCT No

Start Date

End Date

Trial Phase

ICD-9

ICD-10

Applicant

CRO (TW)

CRO (EN)

Trial Scale

Indication (TW)

Indication (EN)

Purpose (TW)

Purpose (EN)

Drug Name (TW)

Drug Name (EN)

ATC Code

Ingredient (TW)

Ingredient (EN)

Dose Type (TW)

Dose Type (EN)

Dose (TW)

Dose (EN)

Evaluation (TW)

Evaluation (EN)

Inclusions (TW)

Inclusions (EN)

Exclusions (TW)

Exclusions (EN)

Taiwan Quantity

Global Quantity

IIT

Hospital

Accept Qty

Contact Name (TW)

Contact Name (EN)

Contact Phone (TW)

Contact Phone (EN)

Contact Email (TW)

Contact Email (EN)

Co-PI

Modify Search

Find Division/Department

All Location

All Division/Department

All Division/Department
Division of Internal Medicine
Division of Surgery
Division of Others

篩選

Developmental Phase

Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others

Trial Status

Not yet recruiting
Active
Completed

Recruitment Status

Not yet recruiting
Recruiting
Completed
Terminated
Stop recruiting
Suspended
Study ended

Trial scale

Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center

The expected start time interval of the test

Trial Applicant

Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization

Important Roles

Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None

Audit by Sponsors/CRO

Sponsors
CRO
None

Investigator-initiated trial(IIT)

Filters

List

196Cases

2017-09-01 - 2019-10-31

Phase III

A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens

Condition/Disease

Hospital-acquired Bacterial Pneumonia, Ventilator-associatedBacterial Pneumonia, or Healthcare-associated BacterialPneumonia Caused by Gram-negative Pathogens
Test Drug

S-649266

Participate Sites
4Sites

Terminated4Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

李文生

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

2016-01-01 - 2019-12-31

Phase I

A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

Condition/Disease

ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)
Test Drug

LDK378

Participate Sites
6Sites

Terminated5Sites

夏德椿

China Medical University Hospital-Taipei

未分科

2016-01-31 - 2017-02-10

Phase I

A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets programmed cell death-1 ligand 1 (PD-L1)) will evaluate the safety, tolerability, PK, IM, and antitumor activity of MEDI4736 in adult patients with solid tumors. A dose exploration cohort will look at the safety profile of Q4W dosing of MEDI4736.

Condition/Disease

NSCLC
Test Drug

MEDI4736 & Tremelimumab

Participate Sites
8Sites

Not yet recruiting1Sites

Terminated7Sites

2018-09-01 - 2019-05-20

Phase III

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody) and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 <50%

Condition/Disease

NSCLC
Test Drug

REGN2810

Participate Sites
11Sites

Not yet recruiting10Sites

鍾飲文

Kaohsiung Municipal Gangshan Hospital

未分科

2018-08-18 - 2022-07-11

Phase III

FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase 1

Condition/Disease

Untreated Advanced Gastric and Gastroesophageal Cancer
Test Drug

FPA144

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated4Sites

白禮源

China Medical University Hospital-Taipei

未分科

2008-09-01 - 2009-06-30

Phase III

Condition/Disease
Test Drug

Participate Sites
14Sites

Terminated14Sites

2015-03-01 - 2017-05-31

Phase III

An Asian, Phase III, multicenter, randomized, double-blind, placebo-controlled, 14-week trial to evaluate the efficacy of DS-5565 in patients with diabetic peripheral neuropathy pain (DPNP), followed by a 52-week open period Mark the extension test.

Condition/Disease

Diabetic peripheral neuropathy pain
Test Drug

DS-5565

Participate Sites
17Sites

Terminated17Sites

2015-03-01 - 2017-05-31

Phase III

AN ASIAN, PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH POST-HERPETIC NEURALGIA FOLLOWED BY A 52-WEEK OPEN-LABEL EXTENSION

Condition/Disease

POST-HERPETIC NEURALGIA
Test Drug

DS-5565

Participate Sites
14Sites

Terminated14Sites

2022-12-05 - 2024-09-30

Phase III

A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

Condition/Disease

Prevention of Ischemic Stroke 、Acute Non-cardioembolic Ischemic Stroke、 High-risk Transient Ischemic Attack
Test Drug

AsundexianPlacebo (for Asundexian)ApixabanPlacebo (for Apixaban)

Participate Sites
23Sites

Not yet recruiting2Sites

Recruiting20Sites

Terminated1Sites

2012-06-29 - 2014-11-28

Phase III

A multi-center, open, uncontrolled phase 3 study to investigate the efficacy and safety of a 4-phasic oral contraceptive SH T00658ID containing estradiol valerate and dienogest in a 28-day regimen for 13 cycles in healthy female subjects

Condition/Disease

oral contraceptive
Test Drug

BAY 86-5027

Participate Sites
6Sites

Terminated6Sites

1 Previous page 16 17 18 19 20

搜尋計畫列表下載細項

全部

試驗主持人
實際收案人數

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB